Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats

Psychopharmacology (Berl). 2005 Nov;182(4):588-96. doi: 10.1007/s00213-005-0138-9. Epub 2005 Oct 19.

Abstract

Rationale: Delta-opioid agonists produce a number of behavioral effects, including convulsions, antinociception, locomotor stimulation, and antidepressant-like effects. The development of these compounds as treatments for depression is limited by their convulsive effects. Therefore, determining how to separate the convulsive and antidepressant-like characteristics of these compounds is essential for their potential clinical use.

Objective: The present study tests the hypothesis that the rate of delta-opioid agonist administration greatly contributes to the convulsive properties, but not the antidepressant-like effects, of delta-opioid agonists.

Materials and methods: The delta-opioid agonist SNC80 (1, 3.2, and 10 mg kg-1 or vehicle) was administered to Sprague-Dawley rats by intravenous infusion over different durations of time (20 s, 20, or 60 min). Convulsions were measured by observation prior to determining antidepressant-like effects in the forced swim test.

Results: Slowing the rate of SNC80 administration minimized delta agonist-induced convulsions without altering the effects of SNC80 in the forced swim test.

Conclusions: These data suggest that delta agonist-induced antidepressant properties are independent of convulsive effects, and that it may be possible to eliminate the convulsions produced by delta agonists, further promoting their potential clinical utility.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Analysis of Variance
  • Animals
  • Antidepressive Agents / administration & dosage*
  • Antidepressive Agents / adverse effects
  • Behavior, Animal / drug effects
  • Benzamides / administration & dosage
  • Benzamides / adverse effects*
  • Dose-Response Relationship, Drug
  • Drug Administration Routes
  • Drug Interactions
  • Male
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacokinetics
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid, delta / antagonists & inhibitors*
  • Restraint, Physical
  • Seizures / etiology*
  • Swimming
  • Time Factors
  • Tritium / pharmacokinetics

Substances

  • Antidepressive Agents
  • Benzamides
  • NTI compound
  • Piperazines
  • Receptors, Opioid, delta
  • Tritium
  • 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide
  • Naltrexone